Images List Premium Download Classic

Psychiatric Disorders

Psychiatric Disorders-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Hydroxmethyl piperidine orexin receptor antagonists
Merck Sharp & Dohme Corp.
November 09, 2017 - N°20170320884

The present invention is directed to hydroxymethyl piperidine compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present ...
Bridged diazepane orexin receptor antagonists
Merck Sharp & Dohme Corp.
November 09, 2017 - N°20170320876

The present invention is directed to bridged diazepane compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present ...
6,5-bicyclic octahydropyrrolopyridine orexin receptor antagonists
Merck Sharp & Dohme Corp.
November 09, 2017 - N°20170320874

The present invention is directed to 6,5-bicyclic octahydropyrrolopyridine compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present ...
Psychiatric Disorders Patent Pack
Download + patent application PDFs
Psychiatric Disorders Patent Applications
Download + Psychiatric Disorders-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Psychiatric Disorders-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Amidoethyl azole orexin receptor antagonists
Merck Sharp & Dohme Corp.
November 09, 2017 - N°20170320856

The present invention is directed to amidoethyl azole compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present ...
Pyrazole, triazole and tetrazole orexin receptor antagonists
Merck Sharp & Dohme Corp.
November 09, 2017 - N°20170319560

The present invention is directed to pyrazole, triazole and tetrazole compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the pyrazole, triazole, and tetrazole compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to ...
Piperidine oxadiazole and thiadiazole orexin receptor antagonists
Merck Sharp & Dohme Corp.
November 02, 2017 - N°20170313693

The present invention is directed to piperidine oxadiazole and thiadiazole orexin compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these ...
Psychiatric Disorders Patent Pack
Download + patent application PDFs
Psychiatric Disorders Patent Applications
Download + Psychiatric Disorders-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Psychiatric Disorders-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Xenon and/or argon treatment as an adjunct to psychotherapy for psychiatric disorders
Merck Sharp & Dohme Corp.
November 02, 2017 - N°20170312308

The present invention relates generally to the fields of treating psychiatric disorders, in particular, anxiety disorders including post-traumatic stress disorder (ptsd) in subjects, e. G., human subjects, by administering a xenon and/or argon containing composition. Treatments can also employ psychotherapy in combination with administration of xenon and/or argon, alone or in combination with additional psychotherapeutic medications to treat ...
Systems and methods for generating biomarkers based on multivariate classification of functional imaging and associated ...
The Brigham And Women's Hospital, Inc.
October 26, 2017 - N°20170309022

Systems and methods for generating biomarkers associated with neuropsychiatric disorders, neurodevelopmental disorders, neurobehavioral disorders, or other neurological disorders are described. In general, the biomarkers are generated based on correlations between functional imaging data and clinical acquired from a subject, as computed using a multivariate classifier. Functional imaging data may include functional magnetic resonance images, or activation maps generated from such ...
Methyl diazepane orexin receptor antagonists
Merck Sharp & Dohme Corp.
October 26, 2017 - N°20170305916

The present invention is directed to methyl diazepane compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present ...
Substituted pyrazoloquinazolinones and pyrroloquinazolinones as allosteric modulators of group ii metabotropic glutamate receptors
Domain Therapeutics
October 26, 2017 - N°20170305913

The present invention provides pyrazoloquinazolinone and pyrroloquinazolinone derivatives of the general formula (i) and pharmaceutical compositions containing them. Moreover, the compounds of formula (i) and the compositions containing them are provided for use in the treatment and/or prophylaxis of conditions associated with altered glutamatergic signalling and/or functions, and/or conditions which can be affected by alteration of glutamate ...
7,8-dihydoxyflavone and 7,8-substituted flavone derivatives, compositions, and methods related thereto
Domain Therapeutics
October 26, 2017 - N°20170305876

Bdnf and trkb activity, such as psychiatric disorders, depression, post-traumatic stress disorder, and autism spectrum disorders, stroke, rett syndrome, parkinson's disease, and alzheimer's disease by administering effective amounts of pharmaceutical compositions comprising compounds disclosed herein to a subject in need thereof. In certain embodiments, it is contemplated that the 7,8-substituted flavone derivatives disclosed herein are prodrugs of 7,8-dihydoxyflavone and analogs.
Triazolopyrazinones as pde1 inhibitors
Domain Therapeutics
October 19, 2017 - N°20170298072

The present invention provides triazolopyrazinones as pde1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.
Imidazopyrazinones as pde1 inhibitors
H. Lundbeck A/s
October 12, 2017 - N°20170291903

The present invention provides imidazopyrazinones as pde1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.
Psychiatric Disorders Patent Pack
Download + patent application PDFs
Psychiatric Disorders Patent Applications
Download + Psychiatric Disorders-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Psychiatric Disorders-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
4-(3-cyanophenyl)-6-pyridinylpyrimidine mglu5 modulators
Heptares Therapeutics Limited
September 28, 2017 - N°20170275265

The disclosures herein relate to novel compounds of formula wherein r1, r2, r3 and r4 and n are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of inflammation, neurological or psychiatric disorders associated with modulating mglu5 receptor function.
Quinazolin-thf-amines as pde1 inhibitors
H. Lundbeck A/s
September 21, 2017 - N°20170267664

The present invention provides quinazolin-thf-amines as pde i inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.
5-ht3 receptor antagonists
H. Lundbeck A/s
September 14, 2017 - N°20170260201

Which are useful for the treatment of diseases treatable by inhibition of 5-ht3 receptor such as emesis, pain, drug addiction, neurodegenerative and psychiatric disorders, and gi disorders. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
Methyl oxazole orexin receptor antagonists
Merck Sharp & Dohme Corp.
September 14, 2017 - N°20170260177

The present invention is directed to methyl oxazole compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present ...
Heteroaryl orexin receptor antagonists
Merck Sharp & Dohme Corp.
September 14, 2017 - N°20170260136

The present invention is directed to heteroaryl compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention ...
Devices, systems and methods for treatment of neuropsychiatric disorders
The Regents Of The University Of California
September 14, 2017 - N°20170259063

The present disclosure relates to methods, devices and systems used for the treatment of mood, anxiety, post traumatic stress disorder, and cognitive and behavioral disorders (collectively, neuropsychiatric disorders) via stimulation of the superficial elements of the trigeminal nerve (“tns”). More specifically, cutaneous methods of stimulation of the superficial branches of the trigeminal nerve located extracranially in ...
Transgenic mouse model for conditional fkbp51 expression and related methods
University Of South Florida
September 14, 2017 - N°20170258940

The subject invention pertains to transgenic non-human animals comprising a transgenic nucleotide sequence, integrated into the genome of the animals, comprising a nucleotide sequence encoding human fkbp51 operably linked to a tetracycline response element. In some embodiments, the transgenic animal comprises an additional transgenic nucleotide sequence, integrated into the genome of the animal, comprising a nucleotide sequence encoding a tetracycline ...
Ester of a phospholipid with conjugated linoleic acid for the treatment of psychiatric disorders with ...
Universita' Degli Studi Di Cagliari
September 14, 2017 - N°20170258924

An ester of a phospholipid with conjugated linoleic acid for use in the therapeutic treatment of or as a food supplement for psychiatric disorders with neuroinflammatory and neurodegenerative basis, such as depression and schizophrenia.
Loading